Retrospective Study
Copyright ©The Author(s) 2019.
World J Gastroenterol. Oct 7, 2019; 25(37): 5667-5675
Published online Oct 7, 2019. doi: 10.3748/wjg.v25.i37.5667
Figure 1
Open in New Tab Full Size Figure Download Figure
Figure 1 Serum soluble mannose receptor levels in different groups of subjects. A: Comparison of serum sMR levels among HBV-ACLF patients, CHB patients, and HCs; B: Comparison of sMR levels among different stages of HBV-ACLF patients. cP < 0.01. sMR: Soluble mannose receptor; HCs: Healthy controls; CHB: Chronic hepatitis B; HBV: Hepatitis B virus; ACLF: Acute-on-chronic liver failure.
Figure 2
Open in New Tab Full Size Figure Download Figure
Figure 2 Comparison of soluble mannose receptor levels between non-survivors and survivors. Serum sMR level in the non-survivor group was significantly higher than that of the survivor group. dP < 0.05. sMR: Soluble mannose receptor.
Figure 3
Open in New Tab Full Size Figure Download Figure
Figure 3 Correlations between serum soluble mannose receptor level and liver injury parameters. rs: Spearman correlation coefficient; sMR: Soluble mannose receptor; HBV: Hepatitis B virus; ACLF: Acute-on-chronic liver failure; MELD: Model for end-stage liver disease; TBIL: Total bilirubin.
Figure 4
Open in New Tab Full Size Figure Download Figure
Figure 4 Kaplan-Meier survival curves of soluble mannose receptor levels for predicting 90-day mortality. sMR: Soluble mannose receptor.
Figure 5
Open in New Tab Full Size Figure Download Figure
Figure 5 Areas under the receiver operating characteristics curves of model for end-stage liver disease score alone and model for end-stage liver disease score plus serum soluble mannose receptor. AUROC: Area under the receiver operating characteristics curve; CI: Confidence interval; MELD: Model for end-stage liver disease; sMR: Soluble mannose receptor.